Sattva Sukun Lifecare reported a standalone net loss of ₹22.35 lakh for the quarter ended June 30, 2026, reversing from a net profit of ₹65.14 lakh in the corresponding period of the previous year. The deterioration was driven by an 80.7% year-on-year collapse in net sales to ₹23.40 lakh from ₹121.55 lakh, coupled with a 15.9% rise in total expenses to ₹60.77 lakh. This performance underscores significant operational headwinds for the distributor as it navigates shrinking revenue streams and elevated cost structures.

The Board of Directors approved the unaudited financial results on August 4, 2026, in compliance with Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Statutory Auditors S S R V & Associates issued a limited review report on both standalone and consolidated figures, confirming no material misstatements. Additionally, the board reviewed the statement of deviations regarding the use of proceeds from the rights issue dated July 7, 2025.

Financial Performance Overview

Standalone net sales declined sharply, while other income remained negligible at zero for the current quarter, contrasting with ₹1.48 lakh in the preceding quarter (Q4FY26). Total expenses surged due to increased purchases of stock-in-trade (₹56.08 lakh vs ₹46.31 lakh YoY) and higher employee benefit expenses (₹7.50 lakh vs ₹5.94 lakh). Although inventory changes provided a credit of ₹43.57 lakh, it was insufficient to offset the revenue drop. Consequently, profit before tax stood at a loss of ₹37.37 lakh, compared to a profit of ₹69.18 lakh in Q1FY25.

On a consolidated basis, net sales fell to ₹64.45 lakh from ₹121.55 lakh in the prior year quarter. Other income contributed ₹11.62 lakh, a marginal increase from ₹0.06 lakh previously. However, total consolidated expenses rose sharply to ₹107.11 lakh from ₹52.43 lakh, primarily due to higher stock purchases (₹194.70 lakh) and employee benefits (₹12.04 lakh). The group reported a consolidated net loss of ₹16.01 lakh, reversing from a profit of ₹65.14 lakh in Q1FY25.

Rights Issue Fund Utilization

The company disclosed deviations in the utilization of funds raised through a rights issue on July 7, 2025. While no deviation was reported for specific objects, the original allocation of ₹4,950 lakh was modified to ₹1,916.16 lakh. As of June 30, 2026, ₹1,891.81 lakh had been utilized. Key allocations included ₹220 lakh for working capital (modified from ₹470 lakh), ₹300 lakh for business expansion (modified from ₹500 lakh), and ₹1,194.16 lakh for investment in existing subsidiary M/s PavaPuri Export Private Limited (modified from ₹3,500 lakh). General corporate purposes saw utilization of ₹116.16 lakh against a modified allocation of ₹116.16 lakh.

What the Numbers Show

The divergence between standalone and consolidated results highlights the impact of inter-company transactions and subsidiary performance. While standalone operations struggled with high inventory costs relative to sales, the consolidated view shows significant other income contributions, suggesting non-operational gains or subsidiary-specific revenues are buffering some losses. However, the overall trend indicates pressure on core distribution margins, with expense growth outpacing any residual income stability. Investors should monitor whether the revised rights issue allocations will stabilize working capital needs in upcoming quarters.

Sattva Sukun Lifecare Limited shareholders have approved the proposal to change the company name to Tavexia Lifecare Limited at an Extra-Ordinary General Meeting (EOGM) held on July 22, 2026. The meeting, conducted via video conferencing, also saw the regularization of two directors and the alteration of the Memorandum of Association (MoA) to align the corporate identity with future business ambitions.

The EOGM commenced at 2:00 PM and concluded at 2:10 PM, with e-voting facilities provided by the National Securities Depository Limited (NSDL). A total of 38 members were present through video conferencing or other audio-visual means. The cut-off date for determining shareholder eligibility was July 15, 2026, while remote e-voting was open from July 19 to July 21, 2026.

The Board recommended the name change and alteration of the Main Objects Clause to grant strategic agility required to diversify into high-potential business areas. The company stated that the rebranding is intended to provide a more distinctive corporate identity. The change is subject to approvals from the Central Registration Centre, Registrar of Companies, and stock exchanges.

Mr. Mit Tarunkumar Brahmbhatt, Chairman and Managing Director, briefed members on the proposals, emphasizing that the regularization of Mr. Sachin Bhanubhai Manseta and Mr. Chirag Dedhia would ensure diverse expertise and robust oversight. M/s Brajesh Gupta & Co, Practicing Company Secretary, served as the scrutinizer for the meeting. The voting results will be announced within two working days and displayed on the company website.